Completed PHASE2 INTERVENTIONAL 2-arm NCT02324985

Phase II Study of AP0302 5% Versus a Vehicle Comparator

Phase II Study of the Effects of AP0302 5% (S-Ibuprofen Topical Gel 5%) Versus the Vehicle Control on Delayed Onset Muscle Soreness of the Elbow Flexors

Sponsor: Aponia Laboratories, Inc.

Conditions Delayed Onset Muscle Soreness Pain

Interventions S-Ibuprofen Topical Gel 5% Vehicle Topical Gel

Updated 8 times since 2017 Last updated: Feb 21, 2019 Started: Jan 31, 2015 Primary completion: Jul 31, 2015 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Delayed Onset Muscle Soreness and Pain and is currently completed. Aponia Laboratories, Inc. leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Mar 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jun 2018 — Mar 2019 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aponia Laboratories, Inc.

Data source: Aponia Laboratories, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pasadena, United States